Edition:
United Kingdom

Pharma Mar SA (PHMR.MC)

PHMR.MC on Madrid SE C.A.T.S.

1.70EUR
22 Feb 2018
Change (% chg)

€-0.00 (-0.18%)
Prev Close
€1.70
Open
€1.72
Day's High
€1.72
Day's Low
€1.67
Volume
397,415
Avg. Vol
1,361,479
52-wk High
€4.26
52-wk Low
€1.45

Select another date:

Fri, Feb 16 2018

BRIEF-Pharma Mar Announces Positive Results Of Its MI13004 Antibody Conjugate

* ANNOUNCES POSITIVE RESULTS OF ITS ANTIBODY CONJUGATE ACTIVE IN BREAST, OVARIAN AND GASTRIC CANCERS Source text for Eikon:

BRIEF-Pharma Mar Licenses Marine-Derived Payloads To Seattle Genetics

* LICENSES FULLY SYNTHETIC MARINE-DERIVED PAYLOADS TO SEATTLE GENETICS FOR USE IN DRUG CONJUGATES

BRIEF-Pharma Mar Says Phase III Trial With Zepsyre In Resistant Ovarian Cancer Not Met Its Primary Endpoint

* CORAIL PHASE III WITH ZEPSYRE IN RESISTANT OVARIAN CANCER HAS NOT MET ITS PRIMARY ENDPOINT Source text for Eikon:

BRIEF-Pharma Mar Requests Re-Examination Process For Aplidin From EMA

* REQUESTS PROCESS OF RE-EXAMINATION FOR APLIDIN FROM THE EUROPEAN MEDICINES AGENCY (EMA)

BRIEF-Pharma Mar Signs Distribution License Agreement For Aplidin In Israel

* SIGNS COMMERCIALIZATION AND DISTRIBUTION LICENSE AGREEMENT FOR APLIDIN WITH MEGAPHARM IN ISRAEL Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-Pharma Mar Says CHMP Against Approving MAA Of Aplidin For Multiple Myeloma Treatment

* THE COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) ISSUES OPINION AGAINST APPROVAL OF THE MARKETING AUTHORIZATION APPLICATION (MAA) OF APLIDIN FOR TREATMENT OF RELAPSED MULTIPLE MYELOMA

BRIEF-Pharma Mar Presents Positive Phase III Trial Results Of Plitidepsin In Multiple Myeloma

* SAYS PRESENTS POSITIVE RESULTS OF ADMYRE PHASE III TRIAL OF PLITIDEPSIN IN MULTIPLE MYELOMA Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-Pharma Mar says IDMC recommends Phase III trial with Zepsyre in small-cell lung cancer patients to continue

* PHASE III TRIAL WITH ZEPSYRE IN SMALL-CELL LUNG CANCER PATIENTS (ATLANTIS) TO CONTINUE WITHOUT CHANGES ON POSITIVE RECOMMENDATION BY IDMC (INDEPENDENT DATA MONITORING COMMITTEE) Source text for Eikon:

BRIEF-Pharma Mar presents positive results from phase II study of lurbinectedin in Ewing's sarcoma

* PRESENTS POSITIVE RESULTS FROM A PHASE II STUDY OF LURBINECTEDIN IN EWING´S SARCOMA

BRIEF-Pharma Mar expects EMA not to approve its Aplidin for multiple myeloma treatment

* SAID ON WEDNESDAY, EXPECTS AN OPINION RECOMMENDING AGAINST APPROVAL OF MARKETING AUTHORIZATION APPLICATION FOR APLIDIN FOR TREATMENT OF MULTIPLE MYELOMA FROM EUROPEAN MEDICINES AGENCY (EMA) BASED ON PRELIMINARY "TREND VOTE" FEEDBACK FROM AGENCY

Select another date: